Shinichiro Fuse

Shinichiro (Shin) Fuse, Ph.D., joined MPM as a Principal in 2016 and is engaged in MPM’s investment identification, due diligence and business development activities across our current BV2014 and OIF funds. He also supports MPM’s relationship with Astellas and is a board observer for Switch Bio. Prior to joining MPM, Shin was Director of Business Development at bluebird bio. At bluebird, he played an instrumental role in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy, and genome editing, including partnerships with Five Prime Therapeutics, Seattle Children’s Research Institute, and the acquisition of Pregenen. Previously, he was an Engagement Manager at Campbell Alliance (inVentiv Health Consulting), where he worked with clients in the life science industry to evaluate business development opportunities, develop commercialization strategies, and support new product launches. Prior to joining Campbell Alliance, Shin was an Associate at PureTech Ventures, where he focused on venture creation activities in the microbiome space and technology due diligence. Shin also serves as a columnist and contributing writer for Nikkei Biotech, the leading journal covering the biotech industry in Japan. Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, a M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.